|
AU2002231736A1
(en)
|
2000-12-22 |
2002-07-08 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
|
US8906864B2
(en)
|
2005-09-30 |
2014-12-09 |
AbbVie Deutschland GmbH & Co. KG |
Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
|
|
FR2892724B1
(fr)
*
|
2005-11-02 |
2008-01-04 |
Lab Francais Du Fractionnement |
Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
|
|
US9896511B2
(en)
|
2007-01-10 |
2018-02-20 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
WO2010062960A2
(en)
|
2008-11-26 |
2010-06-03 |
Cedars-Sinai Medical Center |
METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
|
|
JP5781514B2
(ja)
*
|
2009-09-06 |
2015-09-24 |
プロトエービー リミテッド |
Hsp65由来のペプチド6に特異的なヒト化抗体、その方法及び使用
|
|
PL2510001T3
(pl)
|
2009-12-08 |
2016-06-30 |
Abbvie Deutschland |
Monoklonalne przeciwciało przeciwko białku RGM A do zastosowania w leczeniu zwyrodnienia warstwy włókien nerwowych siatkówki (RNFL)
|
|
EA201291181A1
(ru)
|
2010-05-06 |
2013-05-30 |
Новартис Аг |
Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
|
|
MX2012012928A
(es)
|
2010-05-06 |
2013-05-01 |
Novartis Ag |
Composiciones y metodos de uso para anticuerpos terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
|
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
|
US8766034B2
(en)
|
2010-09-22 |
2014-07-01 |
Cedars-Sinai Medical Center |
TL1A model of inflammation fibrosis and autoimmunity
|
|
JO3375B1
(ar)
*
|
2010-11-08 |
2019-03-13 |
Regeneron Pharma |
أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
|
|
PT2663579T
(pt)
|
2011-01-14 |
2017-07-28 |
Univ California |
Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização
|
|
US8741298B2
(en)
|
2011-02-07 |
2014-06-03 |
Neotope Biosciences Limited |
APOE immunotherapy
|
|
CA2827170A1
(en)
|
2011-02-11 |
2012-08-16 |
David M. Hilbert |
Monovalent and multivalent multispecific complexes and uses thereof
|
|
AU2012259312A1
(en)
|
2011-05-20 |
2013-12-12 |
Government Of The United States, As Represented By The Secretary Department Of Health And Human Services |
Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
|
|
DK2714738T3
(en)
|
2011-05-24 |
2019-01-28 |
Zyngenia Inc |
MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
|
|
AU2012298877B2
(en)
*
|
2011-08-22 |
2018-01-04 |
Emergent Biosolutions Canada Inc. |
Clostridium difficile antibodies
|
|
BR122020013379B1
(pt)
*
|
2011-09-30 |
2023-01-03 |
Teva Pharmaceuticals Australia Pty Ltd |
Anticorpos contra tl1a e seus usos
|
|
EA201490926A1
(ru)
|
2011-11-04 |
2014-09-30 |
Новартис Аг |
Конструкции на основе белка, родственного липопротеинам низкой плотности, 6 (lrp6), и удлинителя полупериода существования
|
|
PL2807192T3
(pl)
|
2012-01-27 |
2019-02-28 |
Abbvie Deutschland |
Kompozycja oraz sposób diagnostyki i leczenia chorób związanych ze zwyrodnieniem neurytów
|
|
TWI660972B
(zh)
|
2012-09-10 |
2019-06-01 |
愛爾蘭商尼歐托普生物科學公司 |
抗mcam抗體及相關使用方法
|
|
WO2014055967A2
(en)
*
|
2012-10-05 |
2014-04-10 |
Neotope Biosciences Limited |
Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
|
|
CN105102067B
(zh)
*
|
2013-01-02 |
2020-03-03 |
艾科诺斯科技股份有限公司 |
结合tl1a的抗体及其用途
|
|
CU24446B1
(es)
|
2013-03-13 |
2019-10-04 |
Prothena Biosciences Ltd |
Un anticuerpo monoclonal humanizado que se une a tau
|
|
AU2014241162A1
(en)
*
|
2013-03-27 |
2015-10-22 |
Cedars-Sinai Medical Center |
Mitigation and reversal of fibrosis and inflammation by inhibition of TL1A function and related signaling pathways
|
|
KR102042174B1
(ko)
|
2013-03-29 |
2019-11-08 |
삼성전자주식회사 |
인간화 및 친화도 성숙된 항 c-Met 항체 및 그의 용도
|
|
US10316083B2
(en)
|
2013-07-19 |
2019-06-11 |
Cedars-Sinai Medical Center |
Signature of TL1A (TNFSF15) signaling pathway
|
|
TWI636065B
(zh)
*
|
2013-08-05 |
2018-09-21 |
伊瑪提克斯生物科技有限公司 |
新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物
|
|
US20160264684A1
(en)
*
|
2013-10-10 |
2016-09-15 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
MX388027B
(es)
|
2013-11-13 |
2025-03-19 |
Pfizer |
Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos.
|
|
PT3116911T
(pt)
|
2014-03-12 |
2019-09-04 |
Prothena Biosciences Ltd |
Anticorpos anti-mcam e métodos de utilização associados
|
|
US10059761B2
(en)
|
2014-03-12 |
2018-08-28 |
Prothena Biosciences Limited |
Anti-Laminin4 antibodies specific for LG4-5
|
|
US10160805B2
(en)
|
2014-07-11 |
2018-12-25 |
New York University |
Methods of treating inflammatory bowel disease by administering tumor necrosis factor-like ligand 1A or an agonistic death-domain receptor 3 antibody
|
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
CA2967595A1
(en)
|
2014-11-12 |
2016-05-19 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
ES2795818T3
(es)
*
|
2015-03-18 |
2020-11-24 |
Seattle Genetics Inc |
Anticuerpos CD48 y conjugados de los mismos
|
|
US20170021020A1
(en)
|
2015-07-23 |
2017-01-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Monoclonal antibody and vaccine targeting filamentous bacteriophage
|
|
TWI703158B
(zh)
|
2015-09-18 |
2020-09-01 |
美商希佛隆公司 |
特異性結合tl1a之抗體
|
|
US10428145B2
(en)
|
2015-09-29 |
2019-10-01 |
Celgene Corporation |
PD-1 binding proteins and methods of use thereof
|
|
WO2017077715A1
(en)
*
|
2015-11-02 |
2017-05-11 |
La Jolla Institute For Allergy & Immunology |
Method and medicament for treating airway and/or lung diseases
|
|
CN116217729A
(zh)
|
2015-11-12 |
2023-06-06 |
思进公司 |
聚糖相互作用化合物及使用方法
|
|
CR20180365A
(es)
|
2015-12-16 |
2018-09-28 |
Amgen Inc |
PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
|
|
WO2017161342A1
(en)
|
2016-03-17 |
2017-09-21 |
Cedars-Sinai Medical Center |
Methods of diagnosing inflammatory bowel disease through rnaset2
|
|
US11046782B2
(en)
|
2016-03-30 |
2021-06-29 |
Musc Foundation For Research Development |
Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
|
|
AU2017259039B2
(en)
|
2016-05-02 |
2024-05-09 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
|
EA201892417A1
(ru)
|
2016-05-02 |
2019-05-31 |
Протена Биосайенсис Лимитед |
Антитела, распознающие тау
|
|
US10752679B2
(en)
|
2016-05-02 |
2020-08-25 |
Prothena Biosciences Limited |
Tau immunotherapy
|
|
MX392069B
(es)
*
|
2016-05-09 |
2025-03-21 |
Bristol Myers Squibb Co |
Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
|
|
US11549146B2
(en)
|
2016-05-20 |
2023-01-10 |
Cedars-Sinai Medical Center |
Diagnosis of inflammatory bowel disease based on genes
|
|
RU2630647C1
(ru)
*
|
2016-05-27 |
2017-09-11 |
Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства |
ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
|
|
EP3515943A4
(en)
*
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
|
|
MX2019002867A
(es)
|
2016-09-19 |
2019-11-12 |
Celgene Corp |
Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
|
|
KR20190082815A
(ko)
*
|
2016-10-26 |
2019-07-10 |
세다르스-신나이 메디칼 센터 |
중화 항-tl1a 단일 클론 항체
|
|
US11401330B2
(en)
|
2016-11-17 |
2022-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
|
CN110913903B
(zh)
|
2017-03-03 |
2024-03-01 |
思进股份有限公司 |
聚糖相互作用化合物和使用方法
|
|
JP7303182B2
(ja)
|
2017-04-21 |
2023-07-04 |
メリタス エルエルシー |
糖尿病関連用途のための方法及び抗体
|
|
CN110881274B
(zh)
|
2017-05-02 |
2024-11-15 |
普罗塞纳生物科学有限公司 |
识别tau的抗体
|
|
JP7368856B2
(ja)
|
2017-07-25 |
2023-10-25 |
トゥルーバインディング,インコーポレイテッド |
Tim-3とそのリガンドとの相互作用の遮断によるがん治療
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
KR102763158B1
(ko)
*
|
2018-04-25 |
2025-02-04 |
프로메테우스 바이오사이언시즈, 인크. |
최적화된 항tl1a 항체
|
|
RU2687609C1
(ru)
*
|
2018-05-30 |
2019-05-15 |
Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства |
Гуманизированное антитело к конформационному эпитопу сз компонента комплемента человека
|
|
CN112955465A
(zh)
|
2018-07-03 |
2021-06-11 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
AU2020214796A1
(en)
|
2019-01-30 |
2021-07-29 |
Truebinding, Inc. |
Anti-Gal3 antibodies and uses thereof
|
|
GB2597851B
(en)
|
2019-02-21 |
2024-05-29 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKP30 and uses thereof
|
|
CA3130754A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
JP7630834B2
(ja)
|
2019-03-03 |
2025-02-18 |
プロセナ バイオサイエンシーズ リミテッド |
タウ認識抗体
|
|
BR112022007720A2
(pt)
|
2019-10-24 |
2022-08-23 |
Prometheus Biosciences Inc |
Anticorpos humanizados para ligante 1a tnf-like (tl1a) e seus usos
|
|
EP4084823A4
(en)
|
2020-01-03 |
2024-05-15 |
Marengo Therapeutics, Inc. |
ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
|
|
WO2021146218A1
(en)
*
|
2020-01-13 |
2021-07-22 |
Truebinding, Inc. |
Anti-gal3 antibodies and methods of use
|
|
US20230192824A1
(en)
*
|
2020-04-02 |
2023-06-22 |
United States Of America As Represented By The Secretary Of The Navy |
Antigen Binding Proteins to Class 5 ETEC Adhesins
|
|
EP4157338A4
(en)
|
2020-05-26 |
2024-11-13 |
TrueBinding, Inc. |
METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
|
|
WO2023141297A2
(en)
*
|
2022-01-21 |
2023-07-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules comprising g6b binder and/or cd34 binder and uses thereof
|
|
WO2024239006A1
(en)
|
2023-05-17 |
2024-11-21 |
Genentech, Inc. |
Anti-tl1a antibody therapeutic methods
|
|
WO2025038473A1
(en)
|
2023-08-11 |
2025-02-20 |
Paragon Therapeutics, Inc. |
Tl1a binding antibodies and methods of use
|
|
CN120530139A
(zh)
*
|
2023-12-29 |
2025-08-22 |
成都优洛生物科技有限公司 |
抗tl1a抗体或其抗原结合片段及应用
|
|
CN120424214A
(zh)
*
|
2024-02-05 |
2025-08-05 |
三生国健药业(上海)股份有限公司 |
一种抗tl1a抗体及其制备方法和用途
|
|
WO2025212534A1
(en)
*
|
2024-04-05 |
2025-10-09 |
Board Of Regents, The University Of Texas System |
Monoclonal antibodies neutralizing marburg and ravn virus
|
|
CN119552252B
(zh)
*
|
2025-01-16 |
2025-11-25 |
华润生物医药有限公司 |
抗tl1a抗体及其制备方法和应用
|